| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
82,110,000 |
| Market
Cap: |
3.40(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$31.73 - $53.69 |
|
| Level
I Sector: |
Consumer Discretionary |
| Level
II Sector: |
Leisure |
| Level
III Sector: |
Restaurants |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ COMPOSITE |
| |
NASDAQ INDUSTRIAL |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
12,005 |
99,487 |
197,241 |
249,694 |
| Total Sell Value |
$596,362 |
$4,824,734 |
$8,130,065 |
$10,494,293 |
| Total People Sold |
2 |
8 |
9 |
12 |
| Total Sell Transactions |
3 |
12 |
19 |
35 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sharp Shalini |
CFO & Executive Vice President |
• – – |
2020-05-18 |
4 |
S |
$73.29 |
$1,612,260 |
D/D |
(21,985) |
100,944 |
|
-29% |
|
| Sharp Shalini |
CFO & Executive Vice President |
• – – |
2020-05-18 |
4 |
OE |
$70.57 |
$1,382,678 |
D/D |
19,593 |
122,929 |
|
- |
|
| Aliski William |
Director |
– • – |
2020-05-18 |
4 |
S |
$74.65 |
$559,875 |
D/D |
(7,500) |
47,924 |
|
-29% |
|
| Aliski William |
Director |
– • – |
2020-05-18 |
4 |
OE |
$40.37 |
$302,775 |
D/D |
7,500 |
55,424 |
|
- |
|
| Fust Matthew K |
Director |
– • – |
2020-05-18 |
4 |
AS |
$75.00 |
$140,625 |
D/D |
(1,875) |
11,000 |
|
29% |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2020-05-18 |
4 |
S |
$74.72 |
$203,374 |
D/D |
(2,722) |
27,312 |
|
-29% |
|
| Huizenga Theodore Alan |
SVP, Controller and PAO |
• – – |
2020-05-15 |
4 |
AS |
$71.00 |
$174,731 |
D/D |
(2,461) |
19,024 |
|
28% |
|
| Huizenga Theodore Alan |
SVP, Controller and PAO |
• – – |
2020-05-15 |
4 |
OE |
$21.00 |
$31,500 |
D/D |
1,500 |
20,219 |
|
- |
|
| Huang Dennis Karl |
EVP & Chief Tech Ops Officer |
• – – |
2020-05-06 |
4 |
D |
$66.26 |
$16,432 |
D/D |
(248) |
34,979 |
|
- |
|
| Bedrosian Camille L |
EVP and Chief Medical Officer |
• – – |
2020-05-06 |
4 |
D |
$66.26 |
$16,499 |
D/D |
(249) |
36,051 |
|
- |
|
| Kassberg Thomas Richard |
CBO & EVP |
• – – |
2020-05-06 |
4 |
D |
$66.26 |
$16,432 |
D/D |
(248) |
101,675 |
|
- |
|
| Harris Erik |
EVP & Chief Commercial Officer |
• – – |
2020-05-06 |
4 |
D |
$66.26 |
$13,848 |
D/D |
(209) |
24,153 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2020-05-06 |
4 |
D |
$66.26 |
$56,454 |
D/D |
(852) |
652,797 |
|
- |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2020-05-06 |
4 |
D |
$66.26 |
$16,432 |
D/D |
(248) |
29,904 |
|
- |
|
| Huizenga Theodore Alan |
SVP, Controller and PAO |
• – – |
2020-05-06 |
4 |
D |
$66.26 |
$9,144 |
D/D |
(138) |
19,680 |
|
- |
|
| Pinion John Richard |
See Remarks |
• – – |
2020-05-06 |
4 |
D |
$66.26 |
$16,432 |
D/D |
(248) |
48,991 |
|
- |
|
| Sharp Shalini |
CFO & Executive Vice President |
• – – |
2020-05-06 |
4 |
D |
$66.26 |
$16,432 |
D/D |
(248) |
103,336 |
|
- |
|
| Fust Matthew K |
Director |
– • – |
2020-04-22 |
4 |
AS |
$65.00 |
$121,875 |
D/D |
(1,875) |
12,875 |
|
28% |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2020-04-19 |
4 |
D |
$58.57 |
$14,525 |
D/D |
(248) |
30,152 |
|
- |
|
| Harris Erik |
EVP & Chief Commercial Officer |
• – – |
2020-04-19 |
4 |
D |
$58.57 |
$12,300 |
D/D |
(210) |
24,362 |
|
- |
|
| Huang Dennis Karl |
EVP & Chief Tech Ops Officer |
• – – |
2020-04-19 |
4 |
D |
$58.57 |
$14,525 |
D/D |
(248) |
35,227 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2020-04-19 |
4 |
D |
$58.57 |
$49,843 |
D/D |
(851) |
653,649 |
|
- |
|
| Sharp Shalini |
CFO & Executive Vice President |
• – – |
2020-04-19 |
4 |
D |
$58.57 |
$14,525 |
D/D |
(248) |
103,584 |
|
- |
|
| Kassberg Thomas Richard |
CBO & EVP |
• – – |
2020-04-19 |
4 |
D |
$58.57 |
$14,525 |
D/D |
(248) |
101,923 |
|
- |
|
| Huizenga Theodore Alan |
SVP, Controller and PAO |
• – – |
2020-04-19 |
4 |
D |
$58.57 |
$8,200 |
D/D |
(140) |
19,818 |
|
- |
|
628 Records found
|
|
Page 11 of 26 |
|
|
0.37 (0.89%) 
